Invest in Siren Biotechnology

Siren Biotechnology is transforming the way we treat cancer. By merging the precision of gene therapy with the power of immunotherapy, we’re creating a universal adeno-associated virus (AAV) immuno-gene therapy. This off-the-shelf treatment is designed to make the next generation of cancer therapy accessible, scalable, and effective across multiple cancers.

Led by world-renowned scientists and biotech innovators, Siren’s team brings expertise from Stanford, UCSF, Duke, Mount Sinai, Roche, and multiple leading gene therapy companies. 

Our pioneering approach to cancer treatment is backed by $28 million in funding from marquee investors, with preclinical data showing curative potential.

Founders Fund, Lux Capital, Innovation Endeavors – VC’s who have backed industry-defining companies like OpenAI, Spotify, Airbnb, and Zocdoc – all agree: Siren is redefining cancer treatment in a $3.2B+ market.

Cancer is the second leading cause of death worldwide, claiming over 10 million lives every year. Gliomas, the most common malignant brain tumors, impact over 20,000 people each year in the U.S. alone. High-grade glioma, the most aggressive and prevalent form of glioma, has a median survival of just 12–18 months.

Traditional treatments, such as chemotherapy and radiation, are limited in their effectiveness, can harm healthy tissues, and fail to improve patient survival rates in some of the deadliest cancers like high-grade gliomas.

The last FDA-approved treatment for adults with high-grade glioma was over 20 years ago. For patients facing the most dire cancers, innovation has largely stagnated, leaving them with few effective options. 

For traditional gene therapy, new solutions often take over a decade and billions of dollars to develop and are focused on a single disease.

At Siren Biotechnology, we’re pioneering a revolutionary approach to treat cancer using an established gene therapy tool called adeno-associated virus (AAV).  

AAV is a safe virus that has been used for decades to deliver gene therapies to patients. Already, it has been used to successfully treat genetic blindness, muscular disorders, and a pediatric form of Parkinson’s disease. It’s exceptional at delivering precise instructions to specific areas of the body, making it the perfect tool for targeting cancer safely and effectively.

We’re using AAV to deliver precision-engineered cytokines, natural proteins that help the body recognize and eliminate cancer cells.

While most cancer treatments rely on chemotherapy, radiation, or surgery, methods that often damage healthy cells and come with serious side effects like nausea, fatigue, and long-term organ damage, Siren’s approach is different.

We’re starting with brain cancers, which include some of the most aggressive and devastating cancers, due to their low survival rates, high unmet need, and streamlined regulatory path. Success here could change outcomes for those facing this devastating disease and pave the way for treating countless other cancers.

In preclinical studies with over 550 animals treated, our therapy has already demonstrated curative potential, completely eliminating tumors and significantly improving survival rates — a major step toward human trials.

Our universal AAV immuno-gene therapy platform is designed to work across multiple cancer types. Our therapies are intended to be broadly applicable to solid tumors regardless of tumor mutation or antigen, thus overcoming the need to re-engineer new therapies for each new cancer type.

Siren's universal approach overcomes a limitation of both traditional gene therapies, which are developed one-to-one for a single disease, and traditional cancer drugs, which to date are ineffective in brain cancers. This also has the potential to reduce development timelines and capital needs per program, allowing us to treat patients faster.

Siren Biotechnology's innovative platform is backed by a robust intellectual property portfolio, including four pending patent families that protect critical advancements in gene therapy delivery, safety, and scalability in cancer treatment.

These patents span innovations such as our AAV immuno-gene therapy platform itself, as well as breakthroughs in AAV genome design that reduce unwanted immune responses, making therapies safer and more effective. 

Additional protections cover regulatory elements that improve the safety and strength of Siren’s gene therapies, and manufacturing methods that ensure the quality and scalability of our drug productions.

Siren Biotechnology’s team is a powerhouse of visionary scientists and biotech innovators from top institutions like Stanford, UCSF, Duke, Mount Sinai, and Roche.

Dr. Nicole Paulk, Siren’s Founder and CEO, is a global expert in AAV gene therapy, having developed next-generation viral platforms now used by dozens of biotech companies. She has shaped FDA regulatory guidance and advised leading biopharma companies, including Sarepta, Astellas, and Dyno Therapeutics.

From breakthroughs in AAV manufacturing and vector engineering to scaling biotech innovations into real-world treatments, our team brings the expertise and industry leadership needed to turn cutting-edge science into life-changing cancer therapies.

Siren Biotechnology is guided by an advisory board of globally recognized leaders whose groundbreaking contributions have shaped the fields of gene therapy, oncology, and immunobiology.

Dr. Samuel Blackman has played a pivotal role in securing the first FDA approval for a pediatric brain cancer treatment in nearly 30 years. 

Dr. Mustafa Khasraw has led numerous clinical trials in neuro-oncology and cancer immunotherapy, redefining how some of the toughest cancers are treated and improving outcomes for thousands of patients.

On the gene therapy front, Dr. Beverly Davidson is a pioneer. As the co-founder of Spark Therapeutics, she helped bring Luxturna – the first FDA-approved AAV gene therapy – to life, leading to its acquisition by Roche in a $4.8B deal. 

Meanwhile, Dr. Leonidas Platanias, Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, runs one of the nation’s top clinical trial centers and is a world expert in the very cytokines we use in our therapy.

The total addressable market for Siren’s groundbreaking therapy is driven by the urgent need for more effective brain cancer treatments.

The global brain tumor therapeutics market grew from $3.03 billion in 2023 to $3.28 billion in 2024 and is expected to continue its rapid expansion, reaching $5.28 billion by 2030 at a CAGR of 8.24%. 

In the U.S. alone, the brain cancer therapeutics market was valued at $966 million in 2022 and is projected to nearly double to $1.87 billion by 2030, growing at a CAGR of 8.6%.

This growth reflects the increasing demand for innovative therapies to combat aggressive and often fatal brain cancers. Siren’s universal AAV immuno-gene therapy platform is uniquely positioned to lead this market, offering a transformative approach that could redefine brain cancer treatment and establish a new standard of care.

Siren Biotechnology operates on a proven therapeutics biotech model, generating future revenue through FDA-approved therapy sales and pharmaceutical partnerships.

Once our universal AAV immuno-gene therapy is available to patients, we aim to generate revenue via treatment insurance reimbursements. In addition to direct sales of our therapy, we will explore potential partnerships that may grant pharmaceutical companies the use of our therapies for specific cancer types. 

These partnerships could generate additional revenue through upfront payments, milestone-based payments, and royalties on future sales. Additionally, these co-development agreements could allow us to expand our reach while maintaining control over our universal platform.

By focusing on deadly brain cancers with no effective therapies, we qualify for expedited regulatory pathways, potentially cutting years off traditional timelines and bringing transformative treatments to patients faster.

We’re accelerating the development of potentially life-saving therapies by utilizing expedited FDA programs designed for high-need, rare diseases.

The gene therapy space has seen a litany of successful exits, with several companies achieving multi-billion-dollar valuations or acquisitions. Siren Biotechnology’s universal AAV platform and unique positioning at the intersection of two high-growth markets — AAV gene therapy and cancer treatment – sets us up for even stronger outcomes.

We're building a company for a successful exit; FDA approval, licensing, and co-developments will help us scale quickly. Siren’s IP bridges the oncology and AAV gene therapy spaces, creating novel partnership opportunities and unique valuation potential.

We’re on a mission to transform the world’s deadliest cancers into treatable diseases. Our universal AAV gene therapy platform is pioneering a scalable, groundbreaking approach to cancer care.

By investing, you’re not just supporting innovation, you’re joining a movement to bring potentially life-saving therapies to patients facing some of the world's deadliest cancers. 

Let’s change the future of cancer care, together. Invest today.